Plymouth Meeting, PA – August 10, 2015: CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, introduces a complete TrialMax® eCOA solution specifically for oncology clinical trials. Developed based on CRF Health's experience of delivering over 100 successful global oncology studies, the solution streamlines data collection by combining an eCOA capture system with intuitive site and patient management tools. Reporting concomitant medication data is also simplified, enabling sponsors to collect complete data while reducing patient and investigator burden.
The length, complexity and increased data demands of oncology trials places a considerable burden on patients, sites and study teams alike. The identification of concomitant medication also brings its own challenges. CRF Health has incorporated its new TrialMax ConMed™ solution into the platform, allowing patients to easily report concomitant medication taken during a trial in real-time and deliver this data to investigators. This not only helps sponsors in identifying which side effects are related to the study drug, but minimizes risk for resulting regulatory submissions.
"Busy site visits and sick patients taking multiple medications means that both investigators and patients may find it difficult to keep track of their condition in a way that meets the requirements of a trial's protocol. We have created this solution to support sponsors with the common problems they face in oncology trials and to collect data which shows the efficacy of the drug in near to real-time”, comments Rauha Tulkki-Wilke, VP Product and Service Management at CRF Health. “In doing so, we have been able to reduce burden on patients and site staff, resulting in improved retention and adherence, two of the biggest challenges in oncology studies.”
Long-Term Analysis Shows Tafinlar Plus Mekinist Reduces Mortality Risk in Stage III Melanoma
November 11th 2024Phase III COMBI-AD trial final analysis shows that 12 months of adjuvant therapy with Tafinlar (dabrafenib) and Mekinist (trametinib) in patients with resected stage III melanoma significantly improved relapse-free survival and distant metastasis-free survival compared to placebo.
Opdivo Combination Shows Superior Survival, Fewer Adverse Effects in Advanced Hodgkin Lymphoma
October 17th 2024The combination of Opdivo (nivolumab) plus chemotherapy significantly improved progression-free survival compared to Adcetris (brentuximab vedotin) plus chemotherapy in patients with advanced stage Hodgkin lymphoma, based on findings from the Phase III S1826 trial.
Zepzelca Plus Tecentriq Significantly Improves Survival in Extensive-Stage Small Cell Lung Cancer
October 15th 2024Preliminary data from the Phase III IMforte trial show the combination of Zepzelca (lurbinectedin) plus Tecentriq (atezolizumab) significantly improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer.